A Case of Nephrotic Syndrome with Nephrotoxicity Induced by Low-Dose Cyclosporin Treatment

We report a 3-year-old girl with steroid resistant nephrotic syndrome (NS) who developed nephrotoxicity by low-dose cyclosporin (CsA) treatment. Initial prednisolone (PSL) treatment and subsequent additional cyclophosphamide treatment were not successful in leading her into remission. The first renal biopsy finding revealed neither a glomerular nor interstitial change. CsA therapy was initiated in addition to ongoing glucocorticoid therapy at 6 months from the time of onset. Proteinuria disappeared 3 weeks later and the patient went into complete remission. After experiencing the first relapse, the patient was gradually weaned from CsA, and treatment continued with 30 to 50 ng/mL of trough concentration. No elevations of the serum creatinine, serum urea, serum potassium, excretion of urinary β2-microglobulin, or urinary N-acetyl-βD-glucosaminidase were demonstrated in the follow-up. A second renal biopsy specimen obtained 1 year later showed a tubulo-interstitial change, containing tubular atrophy and interstitial fibrosis, both of which are consistent with the morphological change associated with CsA nephrotoxicity. A follow-up biopsy should be done in order to evaluate the CsA nephrotoxicity, regardless of the treatment dosage.

[1]  N. Yoshikawa,et al.  Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome , 1999, Pediatric Nephrology.

[2]  R. Hamed Treatment of idiopathic nephrotic syndrome with cyclosporin A in children. , 1997, JN. Journal of Nephrology (Milano. 1992).

[3]  A. Sedman,et al.  Long-term cyclosporine therapy for pediatric nephrotic syndrome: a clinical and histologic analysis. , 1996, Journal of the American Society of Nephrology : JASN.

[4]  N. Yoshikawa,et al.  Long-term cyclosporin in steroid-dependent nephrotic syndrome. , 1995, Contributions to nephrology.

[5]  M. Mihatsch,et al.  Cyclosporin A nephropathy: standardization of the evaluation of kidney biopsies. , 1994, Clinical nephrology.

[6]  M. Mihatsch,et al.  Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. , 1992, The New England journal of medicine.

[7]  M. Mihatsch,et al.  Serial kidney biopsies in patients with nephrotic syndrome treated with cyclosporin. , 1992, Journal of autoimmunity.

[8]  C. Ponticelli,et al.  Safety and tolerability of cyclosporin A (Sandimmun®) in idiopathic nephrotic syndrome , 1991 .

[9]  M. Condamin,et al.  Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. , 1991, Clinical nephrology.

[10]  U. Helmchen,et al.  Cyclosporine treatment of nephrotic syndrome in children. , 1988, Transplantation proceedings.

[11]  P. Niaudet,et al.  Treatment of severe childhood nephrosis. , 1988, Advances in nephrology from the Necker Hospital.

[12]  N. D. De Santo,et al.  Cyclosporin A in nephrotic syndrome of childhood--a 14 month experience. , 1986, The International journal of pediatric nephrology.

[13]  P. Jablonski,et al.  CYCLOSPORINE AND THE ISCHEMIC RAT KIDNEY , 1986, Transplantation.

[14]  M. Mihatsch,et al.  Effect of cyclosporine A on ischemic renal failure in the rat. , 1986, Clinical nephrology.

[15]  J. Teruel,et al.  Mesangial deposits of IgM in patients with the nephrotic syndrome. , 1981, Clinical nephrology.